MedTrace Logo

A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

NCT01302366 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-02-12

Study results available
· View outcomes & findings →

Summary

This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side effects.

Conditions

Interventions

DRUG

TBL12

Sponsors & Collaborators

Principal Investigators

  • Amitabha Mazumder, MD · NYU School of Medicine, Clinical Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01302366 on ClinicalTrials.gov